Propolene weight-loss claim revised
This article was originally published in The Tan Sheet
Executive Summary
The Obesity Research Institute provides adequate substantiation for weight-loss claims promoting Propolene, but agrees to revise certain parts of the claims following an Electronic Retailing Self-Regulations Program inquiry. The National Advertising Review Council division was troubled by claims that the product works "without diet or exercise" and customers can "eat the same way, without having to change anything in their lives." The firm disagreed with ERSP's interpretation of evidence, but has made "certain voluntary changes" in its ads and labeling...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.